BIO Comments on FDA Draft Guidance on ANDAs for Certain Highly Purified Synthetic Peptide Drug Products Referring to Listed Drugs of rDNA Origin
February 4, 2017
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin.
BIO supports enhanced regulatory guidance on considerations for approval of generic and follow-on medicine products, as well as the FDA’s recognition of the appropriateness of the 505(b)(2) application for regulatory assessment of generic medicines and follow-on peptide products.
However, BIO requests FDA provide greater scientific reasoning and specificity on its analysis for the sweeping determination that an ANDA submission may be appropriate for the five specific peptides referenced the guidance. BIO’s comments address this concern in more detail.
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
BIO submitted comments on the Food and Drug Administration’s (FDA) Draft Guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin.
BIO supports enhanced regulatory guidance on considerations for approval of generic and follow-on medicine products, as well as the FDA’s recognition of the appropriateness of the 505(b)(2) application for regulatory assessment of generic medicines and follow-on peptide products.
However, BIO requests FDA provide greater scientific reasoning and specificity on its analysis for the sweeping determination that an ANDA submission may be appropriate for the five specific peptides referenced the guidance. BIO’s comments address this concern in more detail.